As of December 7, 2012, Mesupron, a small molecule serine protease inhibitor developed by the WILEX pharmaceutical company, has completed phase II trials.
A finais de 2012, desenvolveuse Mesupron, unha pequena molécula inhibidora da serina protease pola compañía farmacéutica WILEX, que completou os ensaios en fase II.